Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8+ T-cell activation by bone marrow-derived cells

Gastroenterology

Volumn 123, Issue 4, 2002, Pages 1252-1264

  Bowen, David G ^a,b   Warren, Alessandra ^a,b   Davis, Tom ^a,b   Hoffmann, Matthias W ^c   McCaughan, Geoffrey W ^a,b   De St Groth, Barbara Fazekas ^b   Bertolino, Patrick ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE HEPATITIS; BONE MARROW CELL; BYSTANDER EFFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; HEPATITIS; LIVER CELL DAMAGE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIATION CHIMERA; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; VIRUS INFECTION;

EID: 0036789151     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.36058     Document Type: Article

References (83)

1. Lohr H, Manns M, Kyriatsoulis A, Lohse AW, Trautwein C, Meyer zum Buschenfelde KH, Fleischer B. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991;84:297-302.
2. + LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis. Hepatology 1996;24:1416-1421.
3. Arenz M, Pingel S, Schirmacher P, Meyer zum Buschenfelde KH, Lohr HF. T cell receptor Vbeta chain restriction and preferred CDR3 motifs of liver-kidney microsomal antigen (LKM-1)-reactive T cells from autoimmune hepatitis patients. Liver 2001;21:18-25.
4. Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically proved cases and review of the literature. Am J Med 1980; 69:187-194.
5. Keshavarzian A, Rentsch R, Hodgson HJ. Clinical implications of liver biopsy findings in collagen-vascular disorders. J Clin Gastroenterol 1993;17:219-226.
6. Huang L, Soldevila G, Leeker M, Flavell R, Crispe IN. The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo. Immunity 1994;1:741-749.
7. + T cells triggered by high affinity peptide antigens. J Exp Med 1998;188: 1147-1157.
8. + T cells in the liver during the control and resolution phases of influenza pneumonia. Proc Natl Acad Sci U S A 1998;95: 13812-13817.
9. Crispe IN, Huang L. Neonatal, moribund and undead T cells: the role of the liver in T cell development. Semin Immunol 1994;6: 39-41.
10. Mehal WZ, Azzaroli F, Crispe IN. Antigen presentation by liver cells controls intrahepatic t cell trapping, whereas bone marrow-derived cells preferentially promote intrahepatic t cell apoptosis. J Immunol 2001;167:667-673.
11. Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights. Gastroenterology 2001;120: 250-260.
12. + T cells is transient and depends on avidity. J Immunol 1995;155:2339-2349.
13. Romermann D, Heath WR, Allison J, Bayer B, Sorge Y, Miller JF, Hoffmann MW. Ligand density determines the efficiency of negative selection in the thymus. Transplantation 2001;72:305-311.
14. Schönrich G, Kalinke U, Momburg F, Malissen M, Scmitt-Verhulst AM, Malissen B, Hämmerling G, Arnold B. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 1991;65:293-304.
15. Hua C, Boyer C, Guimezanes A, Albert F, Schmitt-Verhulst AM. Analysis of T cell activation requirements with the use of alloantigens or an anti-clonotypic monoclonal antibody. J Immunol 1986;136:1927-1936.
16. Ceredig R, Lowenthal J, Nabholz M, MacDonald H. Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature 1985;314:98-100.
17. Sarmiento M, Glasebrook AL, Fitch FW. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 1980;25:2665-2672.
18. Bertolino P, Trescol-Biemont MC, Rabourdin-Combe C. Hepatocytes induce functional activation of naive CD8 T cells but fail to promote survival. Eur J Immunol 1998;28:221-236.
19. Spitalny GL, Havell EA. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J Exp Med 1984;159:1560-1565.
20. Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 1992;127:5-24.
21. Gulbenkian AR, Egan RW, Fernandez X, Jones H, Kreutner W, Kung T, Payvandi F, Sullivan L, Zurcher JA, Watnick AS. Interleukin-5 modulates eosinophil accumulation in allergic guinea pig lung. Am Rev Respir Dis 1992;146:263-266.
22. + T cells within the liver. J Immunol 2001;166:5430-5438.
23. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:29-83.
24. Yokoyama WM, Koning F, Kehn PJ, Pereira GMB, Stingl G, Coligan JE, Schevach EM. Characterization of a cell-surface-expressed disulfide-linked dimer involved in murine T cell activation. J Immunol 1988;141:369-376.
25. Hammerling GJ, Rusch E, Tada N, Kimura S, Hammerling U. Localization of allodeterminants on H-2Kb antigens determined with monoclonal antibodies and H-2 mutant mice. Proc Natl Acad Sci U S A 1982;79:4737-4741.
26. Unkeless JC. Characterisation of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 1979;150:580-596.
27. Bhattacharya A, Dorf ME, Springer TA. A shared alloantigenic determinant on Ia antigens encoded by the IA and IE subregions: evidence of I region gene duplication. J Immunol 1981;127: 2488-2495.
28. Harrington LE, Galvan M, Baum LG, Altman JD, Ahmed R. Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J Exp Med 2000;191: 1241-1246.
29. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984;312:548-551.
30. Dialynas D, Quan Z, Wall K, Pierres A, Quintans J, Loken M, Pierres M, Fitch F. Characterization of the murine T cell surface molecule, designated L3T4 identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 1983;131:2445-2451.
31. Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 1981; 11:805-815.
32. Jutila MA, Kroese FG, Jutila KL, Stall AM, Fiering S, Herzenberg LA, Berg EL, Butcher EC. Ly-6C is a monocyte/macrophage and endothelial cell differentiation antigen regulated by interferongamma. Eur J Immunol 1988;18:1819-1826.
33. Coffman RL. Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development. Immunol Rev 1982;69:5-23.
34. + T cells in transgenic mice expressing H-2Kb in the liver. Eur J Immunol 1995;25:1932-1942.
35. Rannie GH, Donald KJ. Estimation of the migration of thoracic duct lymphocytes to non-lymphoid tissues. A comparison of the distribution of radioactivity at intervals following i.v. transfusion of cells labelled with 3H, 14C, 75Se, 99mTc, 1251 and 51Cr in the rat. Cell Tissue Kinet 1977;10:523-541.
36. Goldschneider I, McGregor DD. Migration of lymphocytes and thymocytes in the rat. II. Circulation of lymphocytes and thymocytes from blood to lymph. Lab Invest 1968;18:397-406.
37. Pabst R, Binns RM, Peter M, Licence ST. The physiological role of the lung in lymphocyte migration. Adv Exp Med Biol 1988;237: 553-558.
38. Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS, Greenberger JS, Goff JP. Bone marrow as a potential source of hepatic oval cells. Science 1999;284: 1168-1170.
39. Theise ND, Badve S, Saxena R, Henegariu O, Sell S, Crawford JM, Krause DS. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology 2000; 31:235-240.
40. Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L, Henegariu O, Krause DS. Liver from bone marrow in humans. Hepatology 2000;32;11-16.
41. Alison MR, Poulsom R, Jeffery R, Dhillon AP, Quaglia A, Jacob J, Novelli M, Prentice G, Williamson J, Wright NA. Hepatocytes from non-hepatic adult stem cells. Nature 2000;406:257.
42. Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000;174:21-34.
43. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-809.
44. Fiore G, Piazzolla G, Galetta V, Caccetta L, Schiraldi O, Antonaci S. Liver tissue expression of CD80 and CD95 antigens in chronic hepatitis C: relationship with biological and histological disease activities. Microbios 1999;97:29-38.
45. Okazaki M, Hino K, Fujii K, Hanada H, Nakanishi Y, Kanazawa S, Kobayashi N, Okita K. Immunochemical study of Fas antigen in liver of patients with chronic hepatitis and autoimmune liver disease. Int Hepatol Commun 1995;3:285-289.
46. Schlosser SF, Azzaroli F, Dao T, Hingorani R, Nicholas Crispe I, Boyer JL. Induction of murine hepatocyte death by membranebound CD95 (Fas/APO-1)-ligand: characterization of an in vitro system. Hepatology 2000;32:779-785.
47. Kusters S, Gantner F, Kunstle G, Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996;111:462-471.
48. Nicoletti F, Zaccone P, Xiang M, Magro G, Di Mauro M, Di Marco R, Garotta G, Meroni P. Essential pathogenetic role for interferon (IFN) gamma in concanavalin A-induced T cell-dependent hepatitis: exacerbation by exogenous IFN-gamma and prevention by IFN-gamma receptor-immunoglobulin fusion protein. Cytokine 2000;12:315-323.
49. Toyonaga T, Hino O, Sugai S, Wakasugi S, Abe K, Shichiri M, Yamamura K. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci U S A 1994;91:614-618.
50. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, Hilton DJ. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999;98:597-608.
51. Alexander WS, Starr R, Metcalf D, Nicholson SE, Farley A, Elefanty AG, Brysha M, Kile BT, Richardson R, Baca M, Zhang JG, Willson TA, Viney EM, Sprigg NS, Rakar S, Corbin J, Mifsud S, DiRago L, Cary D, Nicola NA, Hilton DJ. Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction. J Leukoc Biol 1999;66:588-592.
52. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev 2000;174:160-171.
53. Leist M, Gantner F, Bohlinger I, Tiegs G, Germann PG, Wendel A. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am J Pathol 1995;146:1220-1234.
54. Tiegs G, Wolter M, Wendel A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 1989;38:627-631.
55. Kusters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Kunstle G, Bluethmann H, Wendel A, Pfizenmaier K, Kollias G, Grell M. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 1997;27:2870-2875.
56. Kunstle G, Hentze H, Germann PG, Tiegs G, Meergans T, Wendel A. Concanavalin A hepatotoxicity in mice: tumor necrosis factormediated organ failure independent of caspase-3-like protease activation. Hepatology 1999;30:1241-1251.
57. Halloran PF, Autenried P, Ramassar V, Urmson J, Cockfield S. Local T cell responses induce widespread MHC expression. Evidence that IFN-gamma induces its own expression in remote sites. J Immunol 1992;148:3837-3846.
58. Bertolino P, McCaughan GW, Bowen DG. Role of primary intrahepatic T-cell activation in the liver tolerance effect. Immunol Cell Biol 2002;80:84-92.
59. Ando K, Guidotti LC, Cerny A, Ishikawa T, Chisari FV. CTL access to tissue antigen is restricted in vivo. J Immunol 1994;153:482-488.
60. Ehl S, Hombach J, Aichele P, Hengartner H, Zinkernagel RM. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med 1997;185:1241-1251.
61. Zarozinski CC, Welsh RM. Minimal bystander activation of CD8 T cells during the virus-induced polyclonal T cell response. J Exp Med 1997;185:1629-1639.
62. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998;8:177-187.
63. + T cells during an acute virus infection. Immunity 1998;8:167-175.
64. Bertoletti A, D'Elios MM, Boni C, De Carli M, Zignego AL, Durazzo M, Missale G, Penna A, Fiaccadori F, Del Prete G, Ferrari C. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112:193-199.
65. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A 1999;96:5692-5697.
66. Abrignani S. Bystander activation by cytokines of intrahepatic T cells in chronic viral hepatitis. Semin Liver Dis 1997;17:319-322.
67. Abrignani S. Antigen-independent activation of resting T-cells in the liver of patients with chronic hepatitis. Dev Biol Stand 1998; 92:191-194.
68. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-1280.
69. Yokochi S, Ishiwata Y, Hashimoto H, Ninomiya F, Suzuki T. Hepatoprotective effect of propagermanium on Corynebacterium parvum and lipopolysaccharide-induced liver injury in mice. Scand J Immunol 1998;48:183-191.
70. Nishimura T, Ohta A. A critical role for antigen-specific Th1 cells in acute liver injury in mice. J Immunol 1999;162:6503-6509.
71. Ohta A, Sekimoto M, Sato M, Koda T, Nishimura S, Iwakura Y, Sekikawa K, Nishimura T. Indispensable role for TNF-alpha and IFN-gamma at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen. J Immunol 2000;165:956-961.
72. Adamson GM, Billings RE. Cytokine toxicity and induction of NO synthase activity in cultured mouse hepatocytes. Toxicol Appl Pharmacol 1993;119:100-107.
73. Okamoto T, Furuya M, Yamakawa T, Yamamura K, Hino O. TNF-alpha gene expression in the liver of the IFN-gamma transgenic mouse with chronic active hepatitis. Biochem Biophys Res Commun 1996;226:762-768.
74. Brouckaert P, Libert C, Cauwels A, Everaerdt B, Van Molle W, Ameloot P, Gansemans Y, Grijalba B, Takahashi N, Truong MJ, Van Leuven P, Fiers W. Inhibition of and sensitization to the lethal effects of tumor necrosis factor. J Inflamm 1996;47:18-26.
75. Morita M, Watanabe Y, Akaike T. Protective effect of hepatocyte growth factor on interferon-gamma-induced cytotoxicity in mouse hepatocytes. Hepatology 1995;21:1585-1593.
76. Sasagawa T, Hlaing M, Akaike T. Synergistic induction of apoptosis in murine hepatoma Hepa1-6 cells by IFN-gamma and TNF- alpha. Biochem Biophys Res Commun 2000;272:674-680.
77. Schumann J, Wolf D, Pahl A, Brune K, Papadopoulos T, van Rooijen N, Tiegs G. Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol 2000;157:1671-1683.
78. Cookson S, Constantini PK, Clare M, Underhill JA, Bernal W, Czaja AJ, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999;30:851-856.
79. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999;117:645-652.
80. Ando K, Hiroishi K, Kaneko T, Moriyama T, Muto Y, Kayagaki N, Yagita H, Okumura K, Imawari M. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997; 158:5283-5291.
81. Nouri-Aria KT, Sallie R, Mizokami M, Portmann BC, Williams R. Intrahepatic expression of hepatitis C virus antigens in chronic liver disease. J Pathol 1995;175:77-83.
82. Huang SN, Chen TC, Tsai SL, Liaw YF. Histopathology and pathobiology of hepatotropic virus-induced liver injury. J Gastroenterol Hepatol 1997;12(suppl):S195-S217.
83. Kimura H, Nagasaka T, Hoshino Y, Hayashi N, Tanaka N, Xu JL, Kuzushima K, Morishima T. Severe hepatitis caused by Epstein-Barr virus without infection of hepatocytes. Hum Pathol 2001; 32:757-762.